SureTrader SureTrader SureTrader
Home > Boards > US Listed > Medical - Drugs >

Transgenomic Inc. (TBIO)

Add TBIO Price Alert      Hide Sticky   Hide Intro
Moderator: pkdaddy64, bradlee
Search This Board:
Last Post: 1/16/2017 11:11:10 AM - Followers: 76 - Board type: Free - Posts Today: 5


Link to coporate website:

Share Structure
Market Value1 $40,142,705 a/o May 10, 2013
Shares Outstanding 88,225,725 a/o Mar 13, 2013
Float Not Available
Authorized Shares 100,000,000 a/o Aug 02, 2011
Par Value 0.01

Wells Fargo Bank Minnesota, N.A.
Shareowner Services
P.O. Box 64854
St. Paul, MN 55164-0854
Phone: 877-602-7611

Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Our offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine.

Transgenomic offers its WAVE® DHPLC Systems and associated consumables. These systems are specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification and have broad applicability to genetic research. To date there have been over 1600 systems shipped to more than 30 countries.

Transgenomic's SURVEYOR® Mutation Detection Kits and the SURVEYOR Check-It Kit provide reagents and protocols for the detection of mutations in DNA.

Transgenomic's Cytogenetics offering includes HANABI automated chromosome harvesting systems that improve laboratory productivity with consistent quality compared to manual methods.

Transgenomic Clinical Reference Laboratory provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases.

Transgenomic Genomic Research Services is a CRO for pharmacogenomic, translational research and clinical trials.

Colorectal Cancer Testing

Very important AMGEN signs collaberation deal with Mgmt:

"Another potential meaningful near-term contributor to the Lab Services segment (as well as to the Diagnostic Tools segment) relates to the recently consummated agreement with Amgen (NasdaqGS:AMGN) whereby the two companies are collaborating on a KRAS an NRAS gene mutation assay kit to screen patients for colorectal cancer.  The RAScan test is currently available for research use only (RUO) in the U.S. (which will run through Lab Svcs) and for clinical use in Europe - which could help accelerate instrument placements (through Menarini) as well as increase consumables sales"

CRC RAScan™ is a new mutation detection test designed to screen for selected KRAS and NRAS mutations (collectively referred to as “RAS mutations”), in patients with metastatic colorectal cancer (mCRC).The identification of these RAS mutations can give physicians important clinical information to help them make better treatment decisions for their mCRC patients.

KRAS and NRAS are part of the RAS family of genes which encode proteins involved in transmitting signals within cells. When Ras proteins are “switched on” by incoming signals, other genes involved in cell growth, differentiation, and survival are activated. Mutations in KRAS, NRAS and other related genes can lead to Ras proteins becoming permanently activated, causing overactive signaling even in the absence of incoming signals, and can lead to the uncontrolled cell growth that characterizes cancer. Mutations that permanently activate Ras proteins are found in ~25% of human tumors and up to 90% of certain cancers. About 40% of colorectal tumors carry KRAS gene mutations and these mutations have been associated with poor response to EGFR antagonists such as cetuximab and panitumumab. Therefore KRAS mutation status can be used to determine whether or not a patient with colorectal cancer will respond to anti-EGFR therapy.

The CRC RAScan test can identify mCRC patients who have RAS mutations at levels that cannot be detected using traditional Sanger Sequencing methods.

CRC RAScan™ for Colorectal Cancer Tumor Testing is available immediately from Transgenomic’s CLIA-certified laboratory in the United States. For more information on this test, click here.

CRC RAScan Mutation Detection Kits will soon be available in the U.S for research use only. CRC RAScan Mutation Detection Kits include the following kits based on Transgenomic's proprietary SURVEYOR® Nuclease technology:

  • KRAS Exon 2
  • KRAS Exons 3 & 4
  • NRAS Exons 2, 3 & 4

Zacks analyst ~ OUR 2013 OUTLOOK~

We've again made some updates to our model.  We now model 2013 revenue of $32.4 million, implying growth of 3% from 2012.  We look for Laboratory Services and Instruments to generate revenue of $20.0 million (+4%) and $12.4 million (+2%), respectively.  We think net income and EPS come in at ($12.7) million and ($0.14).


New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer

Biomarker Analysis From Phase 3 PRIME ('203) Study and Phase 2 PEAK ('509) Study Link Additional RAS Gene Mutations to Vectibix Clinical Response

THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix® (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer (mCRC). These analyses include the description of new predictive biomarkers of clinical response to Vectibix, activating mutations in KRAS (beyond exon 2) and mutations in NRAS, collectively referred to as RAS.

"Amgen helped establish KRAS gene mutation as a biomarker for lack of response to anti-EGFR treatment," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "The identification of new biomarkers may further help to identify appropriate patients with this incurable disease for such treatment."


Contact Information:
Phone: (402) 452-5437
E-mail: [email protected]

SEC Filings:

Press Releases:

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#1408   USA > " More than 110 million people crudeoil24 01/16/17 11:11:10 AM
#1407   You dont ink deals with Lifelabs unless you pkdaddy64 01/16/17 08:00:12 AM
#1406   Look back at this at the end of pkdaddy64 01/16/17 07:58:09 AM
#1405   This is a long-term hold kind of stock. pkdaddy64 01/16/17 07:57:08 AM
#1404   Folks need to look a little further here tob999 01/16/17 06:52:40 AM
#1403   Closed red down 12% im not understanding what stock1ace1 01/15/17 12:20:12 PM
#1402   Transgenomic, Inc. (TBIO) (NASDAQ:TBIO), today announced that it Martin11 01/15/17 12:17:10 AM
#1401   How does it show more contracts? I don't ghfischeriv 01/14/17 03:17:13 PM
#1400   This weeks PR shows that more contracts will pop. crudeoil24 01/14/17 10:12:04 AM
#1399   Transgenomic Inc. Announces Collaboration With LifeLabs, Shares Skyrocket Zack2000 01/13/17 10:12:16 PM
#1398   With $80 Million dollars traded Today with most pkdaddy64 01/13/17 06:30:15 PM
#1397   * * $TBIO Video Chart 01-13-17 * * ClayTrader 01/13/17 04:23:08 PM
#1396   Dogfight to cover could even get us higher UP Trend 01/13/17 03:44:02 PM
#1395   $1.20+ in a/h possible.... stockdawg44 01/13/17 03:42:45 PM
#1394   at what, a buck? doubtful stockdawg44 01/13/17 03:41:01 PM
#1393   Makes two of us, shorts will not want UP Trend 01/13/17 03:32:41 PM
#1392   Wonder if this ones gonna do an offering Yo-Yo 01/13/17 03:32:04 PM
#1391   Back in at $1 for a scalp....TBIO stockdawg44 01/13/17 03:28:50 PM
#1390   Key is to close above $1 castboy 01/13/17 03:24:37 PM
#1389   Re enter2 $.90 WILL CLOSE @$1.40 rodney45 01/13/17 03:14:31 PM
#1388 rodney45 01/13/17 02:58:24 PM
#1387   This seems to be game changing technology in Tropic17 01/13/17 02:57:39 PM
#1386   Is this where you're getting the $7 target mylar23 01/13/17 02:52:32 PM
#1385   looks like this is going red.lokking to buy castboy 01/13/17 02:47:20 PM
#1384   Sounds great, the mention in the PR about RtRock084 01/13/17 02:44:45 PM
#1383   Consensus or just one analyst? I think there's RtRock084 01/13/17 02:41:37 PM
#1382   $7.00 consensus analyst price target? rodney45 01/13/17 02:34:58 PM
#1381   Do the math..100 million test a year...if tbio Tropic17 01/13/17 02:29:02 PM
#1380   Still be watching bro, but I gotta say The Claw 01/13/17 02:19:15 PM
#1379   So we have no idea how much this RtRock084 01/13/17 02:15:20 PM
#1378   TBIO Market cap = 33.70M @ $1.36 pps. Nickelback 01/13/17 02:08:45 PM
#1377   Multi Dollar Run Potential from these levels imo Alinswift 01/13/17 12:23:52 PM
#1376   The longer this churns here at this level homeboy4u 01/13/17 12:19:27 PM
#1375   Check with (IR) investor relations. crudeoil24 01/13/17 10:47:06 AM
#1374   What is the current market cap? Google Tim696969 01/13/17 10:44:48 AM
#1373   Lol Meztic 01/13/17 10:42:25 AM
#1372   Take it easy on him, poor guy got UP Trend 01/13/17 10:42:02 AM
#1371   Wrong :) Meztic 01/13/17 10:39:46 AM
#1370   Massive 50K block buys coming in big league! crudeoil24 01/13/17 10:36:45 AM
#1369   TBIO > MULTI-DAY, MULTI-WEEK MOVER FROM HERE. Read crudeoil24 01/13/17 10:34:44 AM
#1368   28 million volume in first hour! Shorts in UP Trend 01/13/17 10:33:12 AM
#1366   Same here :) stock1ace1 01/13/17 10:01:03 AM
#1365   Not in at all Meztic 01/13/17 10:01:01 AM
#1364   lol I'm not even in , just watching Meztic 01/13/17 10:00:45 AM
#1363   Not if u bought today ur red stock1ace1 01/13/17 10:00:38 AM
#1362   Gap n trap friday :/ stock1ace1 01/13/17 10:00:18 AM
#1361   Looks super green to me !!! Meztic 01/13/17 09:59:11 AM
#1359   Looks more like a textbook gap fill then homeboy4u 01/13/17 09:35:46 AM
#1358   Gap closing dropping fast stock1ace1 01/13/17 09:30:42 AM
#1357   Gap n trap friday ? stock1ace1 01/13/17 09:23:06 AM